BUSINESS
    Chugai Best-Paying Japan Pharma in FY2021, 25 Drug Makers Pay Average 8.33 Million Yen
    By Reiji Anasako July 4, 2022
    Chugai Pharmaceutical became the best-paying Japanese drug maker for the first time in FY2021 with an average annual pay of 11.56 million yen, according to securities filings tallied by Jiho. Four firms including the Roche group company topped the 10…

    LATEST

    INES Launches Study Group to Propose Stable Healthcare Financing
    July 4, 2022
    The Institute for New Era Strategy (INES) said on June 30 that it has launched a study group on sustainable health finance and new sources of funding, with an eye to comprehensive discussions on the…
    8 VC Firms Certified for AMED Funding Project to Boost Pharma Ecosystem
    July 4, 2022
    The Japan Agency for Medical Research and Development (AMED) said on June 30 that it has selected eight companies as certified venture capitals under its funding project to boost the country’s drug discovery ecosystem.Under the project, AMED will provide funding…
    5 New Probable Cases of Pediatric Hepatitis Reported in Japan
    July 4, 2022
    Japan has reported five new “probable” cases of children with acute hepatitis of unknown etiology, bringing the total number of such detections to 67, the Japanese health ministry said on July 1.According to the WHO’s tentative definition, a probable case…

    COMMENTARY

    Japan Should Accelerate Debate on Legalizing Cannabis-Derived Drugs for Refractory Epilepsies
    By Izuru Ando

    Expert discussions are underway on the lifting of bans on cannabis-derived drugs in Japan. The government is set to create the environment needed to allow for the utilization of such medicines by embracing this policy in its annual “honebuto” paper,…

    COLUMN

    Please Come Back to the Office!
    By Philip Carrigan

    “The Tesla and SpaceX CEO sent an email to employees at both companies on Tuesday saying everyone must spend 40 hours per week in the office. ‘If you don’t show up, we will assume you have resigned. The more senior…

    FY2022 Drug Maker Employment Survey

    Female Manager Ratio at Japan Drug Makers Finally Hits 10%, Foreign Peers Near 25%: Jiho Poll
    By Reiji Anasako

    The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…

    Jiho Survey: FY2022 Drug Price Revision

    Authorized Generics Likely Speeding Up G1/G2 Price Cuts for Off-Patent Brands: Jiho Tally

    Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

    FY2022 Drug Pricing Reform

    MHLW Unveils New List Prices for FY2022 Revision, 18 Off-Patent APIs Face Early “G1” Cuts

    Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

    TRENDS

    15 APIs with 10 Billion Yen-Plus Peak Sales Outlooks Listed in 2021: Jiho Tally

    A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA